Glucotrack Stock News

Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference

Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes

Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept

Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK)

Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes

Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy

Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commerci

Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90

Promising results support the potential of epidural glucose monitoring for simplified disease management for patients with painful diabetic neuropathy

1-for-5 reverse stock split to become effective as of the opening of trading on May 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the �

Continuous blood glucose monitor's preclinical data and sensor longevity modeling to be presented at major diabetes conference

Rutherford, NJ, April 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commerciali

 GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING  Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic Neuropathy Rutherford, NJ, April 16, 2024 -- InvestorsHub NewsWire -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel te...

Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic Neuropathy

    GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR   Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced   Implantable Continuous Blood Glucose Monitor technology could transform lives of patients with diabetes     Rutherford, NJ & Cambridge, UK -- April 2, 2024 -- InvestorsHub NewsWire -- Glu...